The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma
Open accessAbstract
Summary The incidence of hepatocellular carcinoma (HCC) is rapidly increasing due to the prevalence of obesity and non-alcoholic fatty liver disease, but the molecular triggers that initiate disease development are not fully understood. We demonstrate that mice with targeted loss of function point mutations within the AMP-activated protein kinase (AMPK) phosphorylation sites acetyl-CoA carboxylase 1 (ACC1 Ser79Ala) and ACC2 (ACC2 Ser212Ala) have increased liver de novo lipogenesis (DNL) and liver lesions. The same mutation in ACC1 also increases DNL and proliferation human liver cancer cells. Consistent with these findings, a novel, liver specific ACC inhibitor (ND-654), that mimics the effects of ACC phosphorylation, inhibits hepatic DNL and the development of HCC, improving survival of tumor-bearing rats when used alone and in combination with the multi-kinase inhibitor sorafenib. These studies highlight the importance of DNL and dysregulation of AMPK-mediated ACC phosphorylation in accelerating HCC and the potential of ACC inhibitors for treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011) · Science · doi:10.1126/science.1196371 · Cited by 2,600
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238 · cited 2×
“In contrast, S2 tumors, which express several traditional HCC biomarkers like AFP and GPC-3 (Hoshida et al., 2009; Tan et al., 2016), had high ACC1 expression, suggesting that these tumors are readily identifiable in the clinic andmight be an attractive target for ACC inhibition.”
BackgroundSelf-citationFullerton, M. D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z.-P., O'Neill, H. M., Ford, R. J., Palanivel, R., O'Brien, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3372 · Cited by 893
Self-citation
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“Evidence that tumorigenesis requires DNL is based on studies demonstrating that inhibition of acetyl-CoA carboxylase, which promotes DNL, is anti-tumorigenic (Lally et al., 2019).”
BackgroundNew insights into activation and function of the AMPK
Steinberg, G. R., & Hardie, D. G. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00547-x · Cited by 1,006
Self-citationBian, X., Liu, R., Meng, Y., Xing, D., Xu, D., & Lu, Z. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201606 · Cited by 983
Lipid metabolism in cancer: New perspectives and emerging mechanisms
Broadfield, L. A., Pane, A. A., Talebi, A., Swinnen, J. V., & Fendt, S.-M. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.04.013 · Cited by 758
Self-citationAMP-activated protein kinase: the current landscape for drug development
Steinberg, G. R., & Carling, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0019-2 · Cited by 754
Self-citationMetabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma
Du, D., Liu, C., Qin, M., Zhang, X., Xi, T., Yuan, S., Hao, H., & Xiong, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.019 · Cited by 643
The immunological and metabolic landscape in primary and metastatic liver cancer
Li, X., Ramadori, P., Pfister, D., Seehawer, M., Zender, L., & Heikenwalder, M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00383-9 · Cited by 616
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics
Jin, H.-R., Wang, J., Wang, Z.-J., Xi, M.-J., Xia, B.-H., Deng, K., & Yang, J.-L. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01498-2 · Cited by 481
Zuo, X., Chen, Z., Gao, W., Zhang, Y., Wang, J., Wang, J., Cao, M., Cai, J., Wu, J., & Wang, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0839-x · Cited by 447
Lipogenesis inhibitors: therapeutic opportunities and challenges
Batchuluun, B., Pinkosky, S. L., & Steinberg, G. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00367-2 · Cited by 399
Self-citationLipid metabolism in cancer progression and therapeutic strategies
Fu, Y., Zou, T., Shen, X., Nelson, P. J., Li, J., Wu, C., Yang, J., Zheng, Y., Bruns, C., Zhao, Y., et al. (2021) · MedComm · doi:10.1002/mco2.27 · Cited by 393
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state
Hodson, L., & Gunn, P. J. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0256-9 · Cited by 309
Lipid alterations in chronic liver disease and liver cancer
Paul, B., Lewinska, M., & Andersen, J. B. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100479 · Cited by 308
Acetyl-CoA metabolism in cancer
Guertin, D. A., & Wellen, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00543-5 · Cited by 303
The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
Xia, S., Pan, Y., Liang, Y., Xu, J., & Cai, X. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.102610 · Cited by 297
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Nong, S., Han, X., Xiang, Y., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023) · MedComm · doi:10.1002/mco2.218 · Cited by 287
Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies
Wu, X., Xu, M., Geng, M., Chen, S., Little, P. J., Xu, S., & Weng, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01439-y · Cited by 272
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment
Yu, W., Lei, Q., Yang, L., Qin, G., Liu, S., Wang, D., Ping, Y., & Zhang, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01200-4 · Cited by 266
Bates, J., Vijayakumar, A., Ghoshal, S., Marchand, B., Yi, S., Kornyeyev, D., Zagorska, A., Hollenback, D., Walker, K., Liu, K., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.037 · Cited by 230
Self-citationAlkhouri, N., Lawitz, E., Noureddin, M., DeFronzo, R., & Shulman, G. I. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1668374 · Cited by 162
“and improved survival of tumor-bearing rats [49].”
Heida, A., Gruben, N., Catrysse, L., Koehorst, M., Koster, M., Kloosterhuis, N. J., Gerding, A., Havinga, R., Bloks, V. W., Bongiovanni, L., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101349 · Cited by 78
Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis
Zhou, B., Luo, Y., Ji, N., Hu, C., & Lu, Y. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00627-4 · Cited by 75
Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions
Leslie, J., Geh, D., Elsharkawy, A. M., Mann, D. A., & Vacca, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.029 · Cited by 61
Acetyl-CoA metabolism as a therapeutic target for cancer
Chen, G., Bao, B., Cheng, Y., Tian, M., Song, J., Zheng, L., & Tong, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115741 · Cited by 54
Acetyl-CoA: an interplay between metabolism and epigenetics in cancer
Hao, Y., Yi, Q., XiaoWu, X., WeiBo, C., GuangChen, Z., & XueMin, C. (2022) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2022.1044585 · Cited by 26
Metadata
- Authors
- Lally, J. S. V., Ghoshal, S., DePeralta, D. K., Moaven, O., Wei, L., Masia, R., Erstad, D. J., Fujiwara, N., Leong, V., Houde, V. P., Anagnostopoulos, A. E., Wang, A., Broadfield, L. A., Ford, R. J., Foster, R. A., Bates, J., Sun, H., Wang, T., Liu, H., Ray, A. S., Saha, A. K., Greenwood, J., Bhat, S., Harriman, G., Miao, W., Rocnik, J. L., Westlin, W. F., Muti, P., Tsakiridis, T., Harwood, H. J., Kapeller, R., Hoshida, Y., Tanabe, K. K., Steinberg, G. R., & Fuchs, B. C.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 29
- Issue
- 1
- Pages
- 174-182.e5
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W2890605550
- Cited by
- 410
- References
- 36
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.